Novo Nordisk (NVO) said Tuesday that it now expects full-year 2026 adjusted sales and adjusted operating profit to each range from a 6% decline to 0% growth at constant exchange rates, or CER.
Previously, the company expected full-year adjusted sales and adjusted operating profit to each decline 4% to 12%.
The company said Q2 adjusted sales increased by 7% at CER to 78,488 Danish kroner ($12,097) and adjusted operating profit grew 11% at CER to 33,389 Danish kroner.
Shares of Novo Nordisk were down more than 6% in Tuesday trading.
Price: $44.06, Change: $-3.04, Percent Change: -6.45%